A61P 21/00
Drugs for disorders of the muscular or neuromuscular system
A61P21/00 (Drugs for disorders of the muscular or neuromuscular system) appears on 15,408 US grants and 25,162 published applications in this corpus.
Search patents in A61P- Granted patents
- 15,408
- Published applications
- 25,162
- Assignees
- 5,899
- Inventors
- 34,607
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 9 | 0 |
| 1978 | 17 | 0 |
| 1979 | 13 | 0 |
| 1980 | 8 | 0 |
| 1981 | 7 | 0 |
| 1982 | 7 | 0 |
| 1983 | 8 | 0 |
| 1984 | 6 | 0 |
| 1985 | 5 | 0 |
| 1986 | 8 | 0 |
| 1987 | 7 | 0 |
| 1988 | 11 | 0 |
| 1989 | 11 | 0 |
| 1990 | 16 | 0 |
| 1991 | 13 | 0 |
| 1992 | 17 | 0 |
| 1993 | 10 | 0 |
| 1994 | 16 | 0 |
| 1995 | 24 | 0 |
| 1996 | 29 | 0 |
| 1997 | 56 | 0 |
| 1998 | 67 | 0 |
| 1999 | 93 | 0 |
| 2000 | 104 | 0 |
| 2001 | 186 | 73 |
| 2002 | 236 | 441 |
| 2003 | 274 | 691 |
| 2004 | 237 | 941 |
| 2005 | 289 | 988 |
| 2006 | 381 | 942 |
| 2007 | 400 | 1005 |
| 2008 | 464 | 1169 |
| 2009 | 539 | 1393 |
| 2010 | 801 | 1574 |
| 2011 | 813 | 1440 |
| 2012 | 884 | 1491 |
| 2013 | 1026 | 1216 |
| 2014 | 1007 | 1313 |
| 2015 | 986 | 1194 |
| 2016 | 846 | 1262 |
| 2017 | 919 | 1124 |
| 2018 | 805 | 1029 |
| 2019 | 758 | 1044 |
| 2020 | 698 | 870 |
| 2021 | 560 | 821 |
| 2022 | 450 | 704 |
| 2023 | 358 | 658 |
| 2024 | 351 | 695 |
| 2025 | 380 | 631 |
| 2026 | 195 | 453 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions comprising curcuminoids for use in the treatment of muscle soreness6 Oct 2026US 12,751,932 B2Givaudan SA
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Methods of manufacturing microdystrophin gene therapy constructs6 Oct 2026US 12,752,021 B2REGENXBIO Inc.
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Treating muscle weakness with alkaline phosphatases8 Oct 2026US 2026/0306590 A1
- Novel regulatory cassettes for specific expression of genes in muscle stem cells8 Oct 2026US 2026/0306674 A1University of Washington
- Imidazolium salt macrocyclic compound and preparation method therefor and use thereof8 Oct 2026US 2026/0308175 A1Fudan University
- Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy8 Oct 2026US 2026/0308212 A1Research Institute At Nationwide Children's Hospital
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001